Related Experiment Video

Updated: Oct 29, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.0K

House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma

Hisashi Tanida1, Takayasu Nomura1, Yuto Kondo1

  • 1Department of Pediatrics and Neonatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

Asian Pacific Journal of Allergy and Immunology
|July 11, 2021
PubMed

Insights

House dust mite (HDM) sublingual immunotherapy (SLIT) is safe for children with allergic asthma. This treatment for allergic rhinitis showed similar adverse drug reaction rates in asthmatic and non-asthmatic children.

Area of Science:

  • Allergology
  • Pediatric Pulmonology
  • Immunotherapy

Background:

  • House dust mite (HDM) sublingual immunotherapy (SLIT) is clinically effective for pediatric allergic rhinitis.
  • The safety profile of HDM SLIT in pediatric patients with allergic asthma requires further clarification.

Purpose of the Study:

  • To evaluate the risk of adverse drug reactions (ADRs) during the initiation of HDM SLIT in pediatric patients diagnosed with allergic asthma.
  • To assess the safety of SQ HDM SLIT-tablet in children with allergic asthma.

Main Methods:

  • Retrospective analysis of clinical data from pediatric patients (≤ 15 years) initiating SQ HDM SLIT-tablet for allergic rhinitis.
  • Data collected between February 2017 and September 2019.
  • Evaluation of baseline asthma severity and ADRs within the first 4 weeks of treatment.

Main Results:

  • The study included 217 pediatric patients; 45.6% had asthma.
  • Overall, 46.5% of patients experienced ADRs during the initial 4 weeks of therapy.
  • No significant difference in ADR frequency was observed between the asthma and non-asthma groups.

Conclusions:

  • The SQ HDM SLIT-tablet is well-tolerated in pediatric patients with controlled HDM-allergic asthma.
  • HDM SLIT presents a viable treatment option for allergic rhinitis in children, even those with asthma, without significant safety concerns.
  • This suggests HDM SLIT can be considered for managing allergic rhinitis in pediatric populations with comorbid asthma.
Abstract

More Related Videos

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.7K
Murine Model of Allergen Induced Asthma08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.7K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
496
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.0K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
876